Current Liabilities decreased faster than Grace Therapeutics Inc's Cash & cash equivalent, this led to improvement in Grace Therapeutics Inc's Quick Ratio to 8.24, above Grace Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 125 other companies have achieved higher Quick Ratio than Grace Therapeutics Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 480, from total ranking in the fourth quarter 2026 at 2656.

Explain Quick Ratio?
How much Cash & cash equivalents GRCE�s has?
What are GRCE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GRCE/financial-strength

https://api.csimarket.com/api/v1/companies/GRCE/fundamentals

https://api.csimarket.com/api/v1/companies/GRCE/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

GRCE Quick Ratio	(Jun 30 2026) Q1	(Mar 31 2026) Q4	(Dec 31 2025) Q3	(Sep 30 2025) Q2	(Jun 30 2025) Q1
Y / Y Current Liabilities Change	-36.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	617.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	8.24	Subscribe	Subscribe	Subscribe	Subscribe
GRCE's Total Ranking	# 480	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-37.56 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-18.97 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 126
Healthcare Sector	# 200
Overall Market	# 480

Quick Ratio Statistics
High	Average	Low
25.33	6.8	0.34
(Jun 30 2021)		(Sep 30 2024)

Financial Statements
Grace Therapeutics Inc's Current Liabilities	$ 2 Millions	Visit GRCE's Balance sheet
Grace Therapeutics Inc's Cash & cash equivalent	$ 14 Millions	Visit GRCE's Balance sheet
Source of GRCE's Sales		Visit GRCE's Sales by Geography

Cumulative Grace Therapeutics Inc's Quick Ratio

GRCE's Quick Ratio for the trailling 12 Months

GRCE Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-26.92 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	41.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	6.55	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1146	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-10.81 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	30 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to GRCE Financial Strength Comparisons >> Go to Compare GRCE Quick Ratio to its Competitors

On the trailing twelve months basis GRCE Cash & cash equivalent more than doubled by 617.21 % in Q1 2026 year on year, while Current Liabilities plummeted to $2 millions, this led to increase in in Grace Therapeutics Inc's Quick Ratio to 6.55, above GRCE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 488 other companies have achieved higher Quick Ratio than Grace Therapeutics Inc. While Quick Ratio overall ranking has improved so far to 3793, from total ranking during the twelve months ending fourth quarter 2026 at 3805.

Explain Quick Ratio?
How much Cash & cash equivalents GRCE�s has?
What are GRCE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 489
Healthcare Sector	# 976
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
15.5	6.01	0.86
(Dec 31 2021)		(Dec 31 2020)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Relmada Therapeutics Inc	21.72	$ 217.731 Millions	$ 10.023 Millions
Keros Therapeutics Inc	21.20	$ 257.606 Millions	$ 12.153 Millions
Protagonist Therapeutics inc	21.05	$ 782.576 Millions	$ 37.181 Millions
Stablecoin Development Corporation	20.76	$ 7.122 Millions	$ 0.343 Millions
Rhythm Pharmaceuticals Inc	20.65	$ 596.183 Millions	$ 28.868 Millions
Structure Therapeutics Inc	20.31	$ 1,342.700 Millions	$ 66.113 Millions
Scynexis Inc	19.69	$ 114.696 Millions	$ 5.825 Millions
Q32 Bio Inc	19.68	$ 106.270 Millions	$ 5.401 Millions
Damora Therapeutics Inc	19.62	$ 540.515 Millions	$ 27.550 Millions
Kairos Pharma Ltd	19.12	$ 5.067 Millions	$ 0.265 Millions
Minerva Neurosciences Inc	19.02	$ 75.267 Millions	$ 3.958 Millions
Abcellera Biologics Inc	18.05	$ 960.143 Millions	$ 53.189 Millions
Sellas Life Sciences Group Inc	17.29	$ 138.443 Millions	$ 8.006 Millions
Whitehawk Therapeutics Inc	17.17	$ 190.000 Millions	$ 11.069 Millions
Forte Biosciences Inc	17.12	$ 347.331 Millions	$ 20.289 Millions
Ovid Therapeutics Inc	17.01	$ 169.769 Millions	$ 9.980 Millions
Bioage Labs Inc	16.59	$ 318.745 Millions	$ 19.217 Millions
Olema Pharmaceuticals Inc	16.48	$ 873.571 Millions	$ 53.014 Millions
Erasca Inc	16.41	$ 610.496 Millions	$ 37.200 Millions
Janux Therapeutics Inc	16.14	$ 970.913 Millions	$ 60.152 Millions
Edgewise Therapeutics inc	15.86	$ 460.709 Millions	$ 29.042 Millions
Corvus Pharmaceuticals Inc	15.74	$ 215.200 Millions	$ 13.672 Millions
Telomir Pharmaceuticals Inc	15.55	$ 5.170 Millions	$ 0.332 Millions
Rapport Therapeutics Inc	15.34	$ 436.077 Millions	$ 28.424 Millions
Lb Pharmaceuticals Inc	15.32	$ 369.576 Millions	$ 24.128 Millions
Anixa Biosciences Inc	15.09	$ 26.330 Millions	$ 1.745 Millions
Siga Technologies Inc	14.99	$ 117.584 Millions	$ 7.845 Millions
Vyne Therapeutics Inc	14.87	$ 22.925 Millions	$ 1.542 Millions
Alto Neuroscience Inc	14.64	$ 243.733 Millions	$ 16.652 Millions
Tenax Therapeutics Inc	14.62	$ 118.000 Millions	$ 8.073 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.